The urgent need for biomarkers as an objective diagnostic and prognostic tool for PTSD cannot be overstated11,12. Despite an international effort studying military and civilian cohorts where many molecular layers and modalities were investigated13–16, there are, as of yet, no validated blood-based PTSD biomarker panels. Towards this end, one of the more-promising approaches, facilitated by a recent large-scale multi-site collaborative genome-wide association study (GWAS) from the Psychiatric Genomics Consortium for PTSD (PGC-PTSD)17, is genomic profiling using single-nucleotide polymorphisms (SNP’s).
